The essential mycobacterial genes, fabG1 and fabG4, encode 3-oxoacyl-thioester reductases that are functional in yeast mitochondrial fatty acid synthase type 2.
Mycobacterium tuberculosis represents a severe threat to human health worldwide. Therefore, it is important to expand our knowledge of vital mycobacterial processes, such as that effected by fatty acid synthase type 2 (FASII), as well as to uncover novel ones. Mycobacterial FASII undertakes mycolic acid biosynthesis, which relies on a set of essential enzymes, including 3-oxoacyl-AcpM reductase FabG1/Rv1483. However, the M. tuberculosis genome encodes four additional FabG homologs, designated FabG2-FabG5, whose functions have hitherto not been characterized in detail. Of the four candidates, FabG4/Rv0242c was recently shown to be essential for the survival of M. bovis BCG. The present work was initiated by assessing the suitability of yeast oar1Delta mutant cells lacking mitochondrial 3-oxoacyl-ACP reductase activity to act as a surrogate system for expressing FabG1/MabA directed to the mitochondria. Mutant yeast cells producing this targeted FabG1 variant were essentially wild type for all of the chronicled phenotype characteristics, including respiratory growth on glycerol medium, cytochrome assembly and lipoid acid production. This indicated that within the framework of de novo fatty acid biosynthesis in yeast mitochondria, FabG1 was able to act on shorter (C(4)) acyl substrates than was previously proposed (C(8-20)) during mycolic acid biosynthesis in M. tuberculosis. Thereafter, FabG2-FabG5 were expressed as mitochondrial proteins in the oar1Delta strain, and FabG4 was found to complement the mutant phenotype and contain high levels of 3-oxoacyl-thioester reductase activity. Hence, like FabG1, FabG4 is also an essential, physiologically functional 3-oxoacyl-thioester reductase, albeit the latter's involvement in mycobacterial FASII remains to be explored.
Gurvitz
Aner
A
Section of Physiology of Lipid Metabolism, Institute of Physiology, Center for Physiology, Pathophysiology and Immunology, Medical University of Vienna, Schwarzspanierstrasse 17, Vienna 1090, Austria. aner.gurvitz@meduniwien.ac.at
D000429:Alcohol Oxidoreductases / Q000235:genetics* / Q000502:physiology*; D000595:Amino Acid Sequence; D019069:Cell Respiration / Q000235:genetics; D054889:Fatty Acid Synthase, Type II / Q000235:genetics / Q000378:metabolism*; D005800:Genes, Fungal / Q000502:physiology; D005816:Genetic Complementation Test; D008928:Mitochondria / Q000201:enzymology / Q000378:metabolism; D008969:Molecular Sequence Data; D009169:Mycobacterium tuberculosis / Q000235:genetics*; D030781:Organisms, Genetically Modified; D012441:Saccharomyces cerevisiae / Q000201:enzymology* / Q000235:genetics / Q000254:growth & development / Q000378:metabolism; D017386:Sequence Homology, Amino Acid; D008063:Thioctic Acid / Q000378:metabolism
D008063:Thioctic Acid; D000429:Alcohol Oxidoreductases; C023744:acetoacetyl-CoA reductase; D054889:Fatty Acid Synthase, Type II
Mol Microbiol. 2003 Apr;48(1):77-84
12657046
Science. 1994 Jan 14;263(5144):227-30
8284673
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12989-94
14569030
Yeast. 1986 Sep;2(3):163-7
3333305
Mol Cell Biol. 2001 Sep;21(18):6243-53
11509667
J Biol Chem. 1997 Aug 29;272(35):22140-7
9268358
J Bacteriol. 2008 Jun;190(11):4088-90
18375556
J Biomed Biotechnol. 2009;2009:235868
19746209
EMBO J. 1996 Jun 17;15(12):2924-34
8670793
FASEB J. 2009 Nov;23(11):3682-91
19571038
Antimicrob Agents Chemother. 2004 Jan;48(1):242-9
14693546
Adv Enzymol Relat Areas Mol Biol. 1977;45:1-84
21523
Acta Crystallogr D Biol Crystallogr. 2002 Feb;58(Pt 2):303-5
11807257
Biochemistry. 1996 Jul 30;35(30):9797-806
8703953
Antimicrob Agents Chemother. 2002 Nov;46(11):3362-9
12384337
FEBS Lett. 1997 May 19;408(2):217-20
9187370
J Bacteriol. 2007 May;189(10):3721-8
17337570
Anal Biochem. 1976 May 7;72:248-54
942051
Curr Genet. 1997 Dec;32(6):384-8
9388293
Biochem Soc Trans. 2005 Nov;33(Pt 5):1162-5
16246072
J Bacteriol. 2009 Apr;191(8):2683-90
19136596
Clin Microbiol Rev. 2005 Jan;18(1):81-101
15653820
Arch Biochem Biophys. 1958 Nov;78(1):66-82
13595904
Nature. 1998 Jun 11;393(6685):537-44
9634230
Mol Microbiol. 2004 Dec;54(5):1161-72
15554959
Microbiology (Reading). 2002 Apr;148(Pt 4):951-960
11932442
Microbiology (Reading). 2002 Oct;148(Pt 10):2975-2986
12368431
PLoS One. 2009 Apr 28;4(4):e5349
19479006
Antimicrob Agents Chemother. 2003 Sep;47(9):2903-13
12936993
J Mol Biol. 2005 Nov 4;353(4):847-58
16213523
J Biol Chem. 1995 Nov 17;270(46):27453-7
7499202
Microbiology (Reading). 1998 Oct;144 ( Pt 10):2697-2704
9802011
Biochemistry. 2006 Nov 28;45(47):13947-53
17115689
Appl Environ Microbiol. 2008 Aug;74(16):5078-85
18552191
Curr Genet. 1992 Jan;21(1):83-4
1735128
J Biol Chem. 1961 Oct;236:2620-3
13899833
Gene. 1993 Sep 30;132(1):49-55
8406042
J Biol Chem. 1984 Feb 10;259(3):1781-8
6363415
Biochemistry. 1993 Apr 13;32(14):3778-82
8466915